Candida auris is an emerging fungal pathogen responsible for healthcare-associated infections and outbreaks with high mortality around the world. It readily colonizes the skin, nares, respiratory and urinary tract of hospitalized patients, and such colonization may lead to invasive Candida infe...
the current rates of infection necessitate treatment to spare economic losses and potentially fatal consequences. There is a perpetual need for new and more effective drugs to combat bacterial infections. In Canada, expenditures on antimicrobials totaled $786 million in 201414. Notably, antimicrobial...
Antimicrobial photodynamic therapy (aPDT) is an evolving treatment strategy against human pathogenic microbes such as the Candida species, including the emerging pathogen C.auris. Using a modified EUCAST protocol, the light-enhanced antifungal activity of the natural compound parietin was explored. The ...
In this context, the present review aims to provide an overview of the current state of knowledge regarding natural compounds and extracts for xerostomia treatment, paving the way for developing novel therapeutic strategies for this common oral health issue. Keywords: xerostomia; dry mouth; natural...
Amphotericin B, a polyene macrolide polyketide, exhibits a broad spectrum of fungicidal activity against Candida, Aspergillus, and Cryptococcus species [8] and remains a preferred treatment option for severe invasive fungal infections [7]. Caspofungin, a non-ribosomal polyketide derivative, selectively ...
Currently, five classes of antifungal agents, the polyenes, azoles, allylamines, echinocandins and pyrimidines are used for the treatment of fungal infections in human beings [16,17]. Some of them target ergosterol, an essential component of the fungal membrane, either by binding to it (i.e...